Apyx Medical Shares Rise After FDA Expands Clearance for AYON Liposuction Feature

Dow Jones
05/11
 

By Adriano Marchese

 

Apyx Medical shares rose after the company received an expanded U.S. regulatory clearing for its aesthetic device to include an advanced form of liposuction.

Shares rose 7.9% to $3.96 in Monday morning trading. The stock is up almost 40% in the past five days.

The company, which makes surgical aesthetic products, was granted expanded clearance for its AYON Body Contouring System from the Food and Drug Administration. The clearance allows the device to be used for power liposuction, a motor-assisted form of the procedure that uses a rapidly moving tube to make fat removal faster and more efficient.

Chief Executive Charlie Goodwin said that it plans to kick off a limited commercial launch of the power liposuction function to help early adopters to refine training, utilization and overall customer experience before fully scaling up.

 

Write to Adriano Marchese at adriano.marchese@wsj.com

 

(END) Dow Jones Newswires

 

By Adriano Marchese

 

Apyx Medical shares rose after the company received an expanded U.S. regulatory clearing for its aesthetic device to include an advanced form of liposuction.

Shares rose 7.9% to $3.96 in Monday morning trading. The stock is up almost 40% in the past five days.

The company, which makes surgical aesthetic products, was granted expanded clearance for its AYON Body Contouring System from the Food and Drug Administration. The clearance allows the device to be used for power liposuction, a motor-assisted form of the procedure that uses a rapidly moving tube to make fat removal faster and more efficient.

Chief Executive Charlie Goodwin said that it plans to kick off a limited commercial launch of the power liposuction function to help early adopters to refine training, utilization and overall customer experience before fully scaling up.

 

Write to Adriano Marchese at adriano.marchese@wsj.com

 

(END) Dow Jones Newswires

May 11, 2026 11:44 ET (15:44 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10